Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Lancet Oncol. 2020 Aug 28;21(10):1317–1330. doi: 10.1016/S1470-2045(20)30452-6

Figure 2.

Figure 2.

Figure 2.

Panel A: Progression-free survival from randomization in the intention-to-treat population. The results represent data at the second of the three planned interim analysis, with 298 PFS events (75% of 399 planned). HR=hazard ratio.

Panel B: Overall survival in the intention-to-treat population. The results represent data as of the cut-off date used in the planned interim analysis for the primary PFS endpoint.